INmune Bio Inc. INMB 深 滬
等待開盤 08-22 09:30:00 美东时间
2.35
-0.010
-0.42%
華盛通- 最 高2.38
- 今 開2.35
- 成交量 42.05万股
- 最 低 2.315
- 昨 收 2.36
- 總市值 5494.25万
- 52周最高 11.64
- 市盈率 靜 --
- 換手率 1.80%
- 52周最低 1.89
- 委 比 -32.69%
- 總股本 2337.98万
- 歷史最高 30.37
- 量 比 0.80
- 振 幅 2.75%
- 歷史最低 1.89
- 每 手 1
- 風險率 2.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CORRECTION: INmune Bio Q2 Adj. EPS $(0.34) Beats $(0.39) Estimate
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 13.71 percent. This is a 32 percent increase over losses of $(0.50) per share from the same
08-08 06:38
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
INmune Bio's Phase I/II CaRe PC trial of INKmune™ for men with metastatic castration-resistant prostate cancer (mCRPC) met its primary and secondary endpoints, with INKmune™ being well-tolerated and demonstrating an excellent safety profile. Patients with low NK cell activation saw the most significant improvement in biomarkers. INKmune™ converts NK cells into tumor-killing memory-like NK cells, persisting over 100 days and functioning in hypoxic...
08-04 12:00
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
INmune Bio Inc. will host a conference call on August 7, 2025, at 4:30 PM ET to discuss Q2 2025 results and provide a corporate update. The call will be accessible via dial-in numbers or live webcast. The company, focusing on inflammation and immunology, has three product platforms targeting chronic inflammation and cancer. Forward-looking statements involve risks and uncertainties.
07-31 11:00
INmune Bio Releases Video on Alzheimer’s Trial Results
Inmune Bio ( ($INMB) ) just unveiled an update. On July 29, 2025, INmune Bio an...
07-30 05:02
Inmune Bio Reveals Promising XPro™ Trial Results
An update from Inmune Bio ( ($INMB) ) is now available. On July 24, 2025, INmun...
07-26 05:18
INmune Bio to Present New Phase 2 Data on Alzheimer's Drug XPro at AAIC on July 29
INmune Bio Inc. (NASDAQ:INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be released in an oral presentation at the
07-24 19:08
美股大行评级 | 潜在涨幅336.36%！Canaccord Genuity上调ATAI Life Sciences目标价至12美元，维持"买入"评级
Redburn Atlantic：下调Adobe(ADBE)评级至"卖出"，目标价从420美元降至280美元
07-03 11:01
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
